# A Study of Pevonedistat in Adult East Asian Participants

> **NCT02782468** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Pevonedistat 25 mg/m^2
- **DRUG:** Pevonedistat 44 mg/m^2
- **DRUG:** Pevonedistat 10 mg/m^2
- **DRUG:** Pevonedistat 20 mg/m^2
- **DRUG:** Azacitidine 75 mg/m^2

## Key facts

- **NCT ID:** NCT02782468
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-16
- **Primary completion:** 2022-01-25
- **Final completion:** 2022-01-25
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782468, "A Study of Pevonedistat in Adult East Asian Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02782468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*